Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for ...

BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and ...

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Panelists discuss the complexities of managing metastatic melanoma with asymptomatic brain metastases in patients with good ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Panelists discuss City of Hope’s collaborative partnership with community physicians, emphasizing expert evaluation at ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

Panelists emphasize the importance of multidisciplinary collaboration, patient education, and advocacy in managing multiple ...

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...